Results 51 to 60 of about 26,593 (244)

Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review

World Journal of Nuclear Medicine, 2021
Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs.
Thuan Koh, Eva Bezak, David Chan, Gabrielle Cehic   +3 more
doaj   +1 more source

Measurement of 139La(p,x) cross sections from 35–60 MeV by stacked-target activation [PDF]

, 2019
A stacked-target of natural lanthanum foils (99.9119% 139La) was irradiated using a 60 MeV proton beam at the LBNL 88-Inch Cyclotron. 139La(p,x) cross sections are reported between 35–60 MeV for nine product radionuclides. The primary motivation for this
Basunia, MS, Batchelder, JC, Bernstein, LA, Matthews, EF, Morrell, JT, Voyles, AS   +5 more
core   +3 more sources

Targeting Melanin in Melanoma with Radionuclide Therapy

International Journal of Molecular Sciences, 2022
Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and anti-PD-1/PD-L1 immunotherapies into standard of care ...
Kevin J. H. Allen, Mackenzie E. Malo, Rubin Jiao, Ekaterina Dadachova   +3 more
openaire   +2 more sources

Radionuclide monitoring of targeted therapy of iodine-negative differentiated thyroid cancer

Український радіологічний та онкологічний журнал, 2021
Background. Current management of treating iodine-negative metastases of differentiated thyroid cancer has its features. In recent years, tyrosine kinase inhibitors (sorafenib, sunitinib) have been registered and indicated to treat refractory forms of ...
О. І. Солодянникова, Я. В. Кметюк, В. В. Даниленко, Г. Г. Сукач   +3 more
doaj   +1 more source

The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells [PDF]

, 2013
<p>Disulfiram has been used for several decades in the treatment of alcoholism. It now shows promise as an anti-cancer drug and radiosensitizer. Proposed mechanisms of action include the induction of oxidative stress and inhibition of proteasome ...
Ballangrud, Børup, Cen, Cohen, Hald, Maris, Sullivan, Yu, Yuhas   +8 more
core   +1 more source

Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer

Pharmaceuticals, 2022
The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging and therapy of prostate cancer using bombesin peptides that bind to the receptor with high affinity. Targeted copper theranostics (TCTs) using copper radionuclides,
Truc T. Huynh, Ellen M. van Dam, Sreeja Sreekumar, Cedric Mpoy, Benjamin J. Blyth, Fenella Muntz, Matthew J. Harris, Buck E. Rogers   +7 more
doaj   +1 more source

First-in-man evaluation of 124I-PGN650: A PET tracer for detecting phosphatidylserine as a biomarker of the solid tumor microenvironment [PDF]

, 2017
Purpose: PGN650 is a F(ab′) 2 antibody fragment that targets phosphatidylserine (PS), a marker normally absent that becomes exposed on tumor cells and tumor vasculature in response to oxidative stress and increases in response to therapy.
Dehdashti, Farrokh, Freimark, Bruce D, Frye, Jennifer, Frye, Sarah, Laforest, Richard, Liu, Yongjian, Luehmann, Hannah, Shan, Joseph S, Siegel, Barry A, Sultan, Deborah   +9 more
core   +2 more sources

Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium : biological relevance and synthetic strategies [PDF]

, 2012
This review describes how the incorporation of dicarba-closo-dodecarboranes into half-sandwich complexes of ruthenium, osmium, rhodium and iridium might lead to the development of a new class of compounds with applications in medicine. Such a combination
Barry, Nicolas P. E., Sadler, P. J.
core   +1 more source

Targeted radionuclide therapy in combined-modality regimens [PDF]

The Lancet Oncology, 2017
Targeted radionuclide therapy (TRT) is a branch of cancer medicine concerned with the use of radioisotopes, radiolabelled molecules, nanoparticles, or microparticles that either naturally accumulate in or are designed to target tumours. TRT combines the specificity of molecular and sometimes physical targeting with the potent cytotoxicity of ionising ...
Gill, MR, Falzone, N, Du, Y, Vallis, KA
openaire   +4 more sources

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer

Cancer Innovation
In recent years, multidisciplinary treatment strategies have profoundly improved drug responses and survival outcomes of breast cancer (BC) patients. However, there is an urgent need for novel therapies for BC patients who are heavily treated or develop ...
Yujing Tan, Cheng Zeng, Jiani Wang, Fei Ma   +3 more
doaj   +1 more source